Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia. TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, or NNR, and was discovered by Targacept scientists using Targacept’s proprietary drug discovery platform known as PentadTM…

Read the rest here: 
Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia

Related posts:

1. Adolor Corporation Initiates Clinical Testing In Opioid Bowel Dysfunction ProgramAdolor Corporation (NasdaqGM:ADLR) announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single...
2. Intra-Cellular Therapies Announces The Results Of A Phase I PET Study For ITI-007 For The Treatment Of Schizophrenia And Other Psychiatric DisordersIntra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts...
3. Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that the company has initiated a Phase I clinical study...
4. World’s Leading Experts In Schizophrenia To Meet At 26th Annual Pittsburgh Schizophrenia Conference Nov. 13Internationally renowned experts in schizophrenia and other psychotic disorders, researchers and clinicians, patients and their families and friends will gather in Pittsburgh to discuss the latest in research and clinical...
5. Major Schizophrenia Study Finds Striking Similarities Across 37 Countries In Six RegionsAn international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range...
6. BioAlliance Pharma : Entry Into Clinical Phase: Clonidine Lauriad(R) Into Phase II And AMEPTM Into Phase IBioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase...
7. Drug For Alzheimer Disease Does Not Appear To Slow Cognitive DeclineAlthough there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have...
8. Schizophrenia Gene’s Role May Be Broader, More Potent, Than ThoughtUCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia. Scientists have known that...
9. Boehringer Ingelheim Initiates First Phase III Clinical Trial In Ovarian CancerBoehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced...
10. Lundbeck Starts Clinical Phase IIa With Lu AA24493 (cEPO) In Friedreich’s Ataxia In A Study Also Assessing Efficacy Via BiomarkersH. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and tolerability...
11. Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid LeukemiaAmbit Biosciences Corporation announced the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2...
12. Data From Phase 1 Study Confirm High Response Rate Of Micromet’s Blinatumomab In Patients With Non Hodgkins LymphomaMicromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the publication of a poster(1) with new data from...
13. Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary InsomniaActelion Ltd (SIX: ATLN) announced today that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant compared...
14. Ipsen Initiates An Advanced Endometrial Cancer Program With BN83495, Its First-in-Class Steroid Sulfatase Inhibitor First Patient Dosed In Phase IIIpsen (Paris:IPN) announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor,...
15. Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary EndpointsGilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve...